Quanterix Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
450
- Stock Symbol
-
QTRX
- Investments
-
4
- Share Price
-
$2.03
- (As of Thursday Closing)
Quanterix General Information
Description
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Contact Information
Website
www.quanterix.comCorporate Office
- 900 Middlesex Turnpike
- Building 1
- Billerica, MA 01821
- United States
Corporate Office
- 900 Middlesex Turnpike
- Building 1
- Billerica, MA 01821
- United States
Quanterix Stock Performance
As of 19-Nov-2026, Quanterix’s stock price is $2.03. Its current market cap is $96.4M with 47.5M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.03 | $2.07 | $1.76 - $8.77 | $96.4M | 47.5M | 710K | -$2.36 |
Quanterix Financials Summary
As of 30-Sep-2026, Quanterix has a trailing 12-month revenue of $148M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 115,315 | 202,392 | 154,482 | 748,954 |
| Revenue | 147,907 | 138,654 | 135,436 | 121,139 |
| EBITDA | (86,612) | (101,913) | (44,396) | (35,184) |
| Net Income | (111,185) | (107,150) | (38,531) | (28,354) |
| Total Assets | 300,437 | 418,766 | 406,533 | 428,567 |
| Total Debt | 31,362 | 37,239 | 37,371 | 41,464 |
Quanterix Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Quanterix Comparisons
Industry
Financing
Details
Quanterix Competitors (9)
One of Quanterix’s 9 competitors is Seer, a Formerly VC-backed company based in Redwood City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Seer | Formerly VC-backed | Redwood City, CA | ||||
| Revvity | Corporation | Waltham, MA | ||||
| Bio-Rad Laboratories | Corporation | Hercules, CA | ||||
| Siemens Healthineers | Corporation | Forchheim, Germany | ||||
| Meridian Bioscience | Private Equity-Backed | Cincinnati, OH |
Quanterix Patents
Quanterix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026006441-A1 | Systems and methods for improving biomarker detection results using multiple biomarkers | Pending | 26-Jun-2024 | ||
| WO-2026006441-A8 | Systems and methods for improving biomarker detection results using multiple biomarkers | Pending | 26-Jun-2024 | ||
| AU-2025232769-A1 | Systems and methods for biological sample imaging and analysis | Pending | 06-Mar-2024 | ||
| WO-2025188900-A1 | Systems and methods for biological sample imaging and analysis | Pending | 06-Mar-2024 | ||
| WO-2025188900-A8 | Systems and methods for biological sample imaging and analysis | Pending | 06-Mar-2024 | G01N21/6458 |
Quanterix Signals
Quanterix Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Quanterix Acquisitions (4)
Quanterix’s most recent deal was a Merger/Acquisition with Akoya Biosciences for . The deal was made on 08-Jul-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Akoya Biosciences | 08-Jul-2025 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Emission | 08-Jan-2025 | Merger/Acquisition | Other Commercial Products | ||
| UmanDiagnostics | 01-Aug-2019 | Merger/Acquisition | Diagnostic Equipment | ||
| Aushon BioSystems | 30-Jan-2018 | Merger/Acquisition | Discovery Tools (Healthcare) |
Quanterix ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
23.96 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Quanterix Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Emission | Georgetown, TX | 2020 | |
| UmanDiagnostics | Umea, Sweden | 2006 |
Quanterix FAQs
-
When was Quanterix founded?
Quanterix was founded in 2007.
-
Where is Quanterix headquartered?
Quanterix is headquartered in Billerica, MA.
-
What is the size of Quanterix?
Quanterix has 450 total employees.
-
What industry is Quanterix in?
Quanterix’s primary industry is Diagnostic Equipment.
-
Is Quanterix a private or public company?
Quanterix is a Public company.
-
What is Quanterix’s stock symbol?
The ticker symbol for Quanterix is QTRX.
-
What is the current stock price of Quanterix?
As of 19-Nov-2026 the stock price of Quanterix is $2.03.
-
What is the current market cap of Quanterix?
The current market capitalization of Quanterix is $96.4M.
-
What is Quanterix’s current revenue?
The trailing twelve month revenue for Quanterix is $148M.
-
Who are Quanterix’s competitors?
Seer, Revvity, Bio-Rad Laboratories, Siemens Healthineers, and Meridian Bioscience are some of the 9 competitors of Quanterix.
-
What is Quanterix’s annual earnings per share (EPS)?
Quanterix’s EPS for 12 months was -$2.36.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process